Novo Nordisk's Weight-Loss Drug Trial Disappoints: What Went Wrong? investing pharmacy stocks [YUOFRIVRjEi]
| 1h 28m 28s | Video has closed captioning.
Novo Nordisk shares took a major hit after their latest weight-loss drug trial fell short of expectations. In this video, we break down what went wrong with CagriSema, how it compares to competitors like Eli Lilly, and what this means for the future of the weight-loss drug market. Is this a buying opportunity or a sign to wait? Watch now for detailed insights and analysis! #curve diet pills #amazon keto iq gummies #mach 5 keto acv reviews
Aired: December 27, 2024
Buy Now:
Novo Nordisk's Weight-Loss Drug Trial Disappoints: What Went Wrong? investing pharmacy stocks [YUOFRIVRjEi]
Fixed iFrame
Responsive iFrame
Problems Playing Video? | Closed Captioning
